The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Imatinib for FIP1L1-PDGFRA Chronic Eosinophilic Leukemia

Tyrosine kinase inhibitor for myeloid neoplasm with PDGFRA rearrangement

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Imatinib for FIP1L1-PDGFRA Chronic Eosinophilic Leukemia?

Chronic eosinophilic leukemia with FIP1L1-PDGFRA fusion is a myeloid neoplasm classified by WHO 2022 as a distinct entity.

The fusion creates a constitutively active platelet-derived growth factor receptor alpha kinase driving eosinophil proliferation.

Imatinib at low doses (100 to 400 mg daily) produces complete hematologic and molecular responses in most patients.

Diagnosis confirmed by FISH or RT-PCR for FIP1L1-PDGFRA fusion in peripheral blood or bone marrow.

Lifelong therapy is generally recommended; discontinuation trials show high relapse rates.

Symptoms

Marked peripheral blood eosinophilia (often greater than 1500 per microliter sustained).
Cardiac involvement: endomyocardial fibrosis, restrictive cardiomyopathy, valvular damage.
Pulmonary symptoms: cough, dyspnea, eosinophilic pneumonitis.
Skin manifestations: pruritus, rash, urticaria.
Hepatosplenomegaly and constitutional symptoms (fatigue, weight loss).

Risk Factors

Male predominance (greater than 90 percent of cases).
Adult onset typically in third to fifth decades.
Established cardiac involvement at diagnosis worsens prognosis.
Delayed diagnosis allows progressive end-organ damage.
Atypical presentation may delay molecular testing for FIP1L1-PDGFRA.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent unexplained eosinophilia on multiple complete blood counts.
  • New cardiac symptoms with elevated troponin or NT-proBNP.
  • Worsening dyspnea or chest discomfort during evaluation.
  • Skin manifestations not responding to typical allergy management.
  • Loss of molecular response while on imatinib treatment.

Treatment Methods

01
Imatinib 100 mg daily as starting dose; many patients achieve molecular response at this dose.
02
Dose escalation to 400 mg if suboptimal response within 3 to 6 months.
03
Initial corticosteroid coverage to prevent imatinib-induced cardiac decompensation in patients with troponin elevation.
04
Molecular monitoring with quantitative RT-PCR every 3 to 6 months.
05
Long-term low-dose maintenance; treatment-free remission attempts not yet standard.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.